^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

RELA expression

i
Other names: RELA, RELA Proto-Oncogene, NF-KB Subunit 2, Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 3, V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A, Nuclear Factor NF-Kappa-B P65 Subunit, Transcription Factor P65, NFKB3, P65, NF-Kappa-B Transcription Factor P65, NF-Kappa-B P65delta3, CMCU
Entrez ID:
Associations
Trials
1year
MiRNAs and tempol therapeutic potential in prostate cancer: a preclinical approach. (PubMed, J Mol Histol)
Their increase is mainly linked to increased cell death and delayed CaP aggressivenes. Thus, tempol's capacity for miRNA-mediated gene silencing to decrease tissue proliferation and cell survival processes is part of its tissue mechanics.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • MIR155 (MicroRNA 155) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • Let-7c (MicroRNA Let-7c) • MIR26A1 (MicroRNA 26a-1) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA) • RELA (RELA Proto-Oncogene)
|
RELA expression
1year
Regulator of G protein signaling-1 facilitates ovarian cancer development by modulating NF-kB signal pathway. (PubMed, Sci Rep)
Additionally, blocking the NF-kB pathway was shown to impede RGS1-induced proliferation, and overexpression of p65 partially reversed the effects of RGS1 deletion, promoting the tumorigenic properties of OC cells. These findings suggest that RGS1 could be a valuable biomarker for predicting prognosis and a potential novel therapeutic target for OC treatment.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CD24 (CD24 Molecule) • RELA (RELA Proto-Oncogene)
|
RELA expression
1year
Biomimetic Fe3O4 Nanozymes Promote Apoptosis in Breast Cancer Cell Lines via Free Radical Scavenging and Inhibition of RelA/p65. (PubMed, Curr Pharm Biotechnol)
This is the first report on the antiproliferative and immunomodulatory activities expressed by the biomimetic iron oxide nanozyme.
Preclinical • Journal
|
RELA (RELA Proto-Oncogene)
|
RELA expression
1year
Tenuigenin inhibits osteosarcoma growth via CIP2A/PP2A/NF-κB axis. (PubMed, Cancer Chemother Pharmacol)
TEN suppressed OS growth via CIP2A/PP2A/NF-κB axis, indicating that it would be a novel drug for treating OS.
Journal
|
CIP2A (Cellular Inhibitor Of PP2A) • RELA (RELA Proto-Oncogene)
|
RELA expression
1year
miR-105-5p/PTEN Axis Modulates the Immune Response and Epithelial-Mesenchymal Transition of Colon Cancer via NF-κB Activation. (PubMed, J Biochem Mol Toxicol)
It also distinctly deactivated the NF-κB pathway. To sum up, these data indicated that miR-105-5p depletion might impede EMT, yet enhance the immune response in CC by elevating PTEN expressions via deactivation of the NF-κB pathway.
Journal
|
PTEN (Phosphatase and tensin homolog) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • NFKBIA (NFKB Inhibitor Alpha 2) • MIR105 (MicroRNA 105) • RELA (RELA Proto-Oncogene)
|
PTEN expression • RELA expression
1year
Postbiotic metabolites derived from lactobacillus fermentum as potent antiproliferative bioresources on HeLa cells with promising biocompatibility. (PubMed, BMC Complement Med Ther)
The results of the bioactivity assay revealed that these postbiotics had suitable anticancer influences on the cervical cancer model (HeLa cells) by increasing BAX, caspase8, and caspase9, followed by a decrease in BCl-2, iKB (Inhibitor of nuclear factor kappa-B), and RelA gene expressions. Thus, the findings of this study signify that the postbiotic derivate from Lactobacillus strains isolated from indigenous Iranian dairy products could be regarded as a topical treatment with a promising curative index due to their effectiveness on cervical malignancy cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP8 (Caspase 8)
|
RELA expression
1year
A Review on Hepatoprotective Effect of Chrysin: Preclinical Implications and Molecular Cascades Came into Focus. (PubMed, Curr Diabetes Rev)
Chrysin prevented cyclophosphamide, doxorubicin, cisplatin, methotrexate, paracetamol, alcohol, carbon tetrachloride, tert-butyl hydroperoxide (tBHP) and thioacetamide. Chrysin's most common hepatoprotective biochemical and molecular mechanisms involve the ability to control enzyme synthesis, scavenge free radicals, boost the antioxidant response, induce apoptosis, and modify the synthesis of proinflammatory and profibrotic cytokines.Chrysin is a valuable nutraceutical with broad therapeutic feasibility, but to confirm its representative hepatoprotective potential, clinical studies are advised. It would also be interesting to use cutting-edge drug delivery techniques or include bio-enhancers.
Preclinical • Review • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • TWIST1 (Twist Family BHLH Transcription Factor 1) • RELA (RELA Proto-Oncogene)
|
MAP2K1 overexpression • RELA expression
|
cisplatin • doxorubicin hydrochloride • cyclophosphamide • methotrexate
1year
Evaluation of the effect of phellodendrin application on rats creating an experimental model of non-compression lumbar disc herniation on the NF-κB-related inflammatory signaling pathway. (PubMed, J Orthop Surg Res)
In this animal experiment, phellodendrine was found to significantly reduce the expression level of p65 mRNA, decrease the release of inflammatory cytokines, and alleviate lumbar disc pain.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • IL1B (Interleukin 1, beta) • RELA (RELA Proto-Oncogene)
|
RELA expression
1year
The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer. (PubMed, PLoS One)
Furthermore, we observed that NF-κB mediated HE4 expression at the transcriptional level. Our data also suggests that there is a regulatory role for HE4 in the expression of α5-Integrin, a crucial adhesion molecule in ovarian cancer metastasis; HE4 knockdown corresponded with reduced α5-Integrin expression, cell migration and cell adhesion to fibronectin.
Journal • PARP Biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • RELA (RELA Proto-Oncogene)
|
RELA expression
1year
The IL-33/ST2 Axis Affects Adipogenesis Through Regulating the TRAF6/RelA Pathway. (PubMed, Int J Mol Sci)
This further attenuates the expression of RelA, ultimately resulting in the suppression of adipogenesis in 3T3-L1 preadipocytes. This study reveals a new mechanism by which the IL-33/ST2 axis regulates the differentiation of preadipocytes and provides a new idea for improving obesity prevention.
Journal
|
IL33 (Interleukin 33) • ST2 (Suppression Of Tumorigenicity) • TRAF6 (TNF Receptor Associated Factor 6)
|
RELA expression
over1year
The effects of acetylated cordycepin derivatives on promoting vascular angiogenesis and attenuating myocardial ischemic injury. (PubMed, Heliyon)
Additionally, administration of DAAA improved cardiac function following coronary artery ligation in mice. DAAA could be considered a promising adjunctive therapy to prevent post-MI heart failure through promoting angiogenesis.
Journal
|
RELA (RELA Proto-Oncogene)
|
RELA expression
|
cordycepin (OVI-123)
over1year
Study on the Anti-Atherosclerotic Mechanisms of Xin-Tong-Tai Granule Through Network Pharmacology, Molecular Docking, and Experimental Validation. (PubMed, J Inflamm Res)
XTTG mitigates AS primarily through anti-inflammatory and autophagy-modulating mechanisms, particularly via inhibition of NF-κB p65 expression. These findings underscore the potential of CM in treating AS and support its further clinical exploration.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • APOE (Apolipoprotein E) • RELA (RELA Proto-Oncogene)
|
RELA expression